创新药强复苏！CRO二波行情已启动？这波机会别错过！

Core Viewpoint - The domestic pharmaceutical industry is expected to experience a significant turning point in 2025, with the innovative drug sector emerging from an adjustment period to achieve a strong recovery, becoming the core growth engine of the pharmaceutical sector [5][21]. Group 1: Market Trends and Investment Dynamics - In January 2026, the CRO sector showed a clear net inflow of funds, with strong technical signals indicating a potential upward trend [5]. - The investment and financing market is recovering, with the scale of BD (Business Development) overseas reaching a historical high, alongside improvements in IND (Investigational New Drug) application and review efficiency [7]. - The first three quarters of 2025 saw the medical health primary market financing amount reach 79.53 billion yuan, a year-on-year increase of 22.4%, indicating a shift in capital allocation towards high-certainty clinical projects [12]. Group 2: Financing and BD Developments - In 2025, the total transaction amount for innovative drug BD reached 135.7 billion USD, with an upfront payment of 7 billion USD, marking a historical high [13]. - The Hong Kong stock market's financing channels have fully recovered, with IPOs and refinancing driving the market, primarily for innovative drug companies in clinical advancement stages [12]. Group 3: R&D and Regulatory Environment - The innovative drug R&D sector is witnessing a substantial recovery, with both IND application volume and approval efficiency significantly improving, leading to a steady increase in orders for the CRO industry [14][19]. - In 2025, the CDE (Center for Drug Evaluation) accepted 1,878 IND applications, a year-on-year increase of 13.34%, with class 1 innovative drug applications being the main growth driver [17]. - The NMPA (National Medical Products Administration) completed 1,897 IND application approvals in 2025, with a high approval rate for class 1 innovative drugs at 96.53% [19]. Group 4: Competitive Landscape and Future Outlook - The CRO industry is experiencing comprehensive development benefits, with leading companies leveraging their technological, scale, and compliance advantages to dominate the market [8][20]. - The global regulatory shift and digital transformation in clinical execution are expanding market space for CROs, enhancing the competitive barriers for leading firms [20]. - The recovery of the innovative drug industry presents historic development opportunities for the CRO sector, with multiple favorable factors indicating a sustained increase in industry prosperity [21].